European Journal of Pharmacology
October 8, 1997
Isabelle M Maisonneuve, K E Visker, G L Mann et al.
20 citations
The purpose of this study was to clarify the effects of iboga agents on cocaine-induced hyperactivity. Both inhibition and enhancement of cocaine-induced activity by ibogaine have been reported. In the present study, rats were treated with either ibogaine (40 mg/kg, i.p.), noribogaine (40 mg/kg, i.p.), 18-methoxycoronaridine (40 mg/kg, i.p.), or saline, 1 or 19 h prior to the administration of...
Pharmacology, Biochemistry, and Behavior
October 1, 1997
Amir H Rezvani, David H Overstreet, Y Yang et al.
78 citations
We previously reported that single administration of ibogaine, an indol alkaloid with antiaddictive properties, dose dependently reduced alcohol intake in three strains of alcohol-preferring rats. The present study examined the effect of different doses of a newly developed nontoxic ibogaine analogue, 18-methoxycoronaridine (18-MC), on alcohol intake. Selectively bred alcohol-preferring rats...
Pharmacology, Biochemistry, and Behavior
September 1, 1997
Scott Helsley, David Fiorella, R A Rabin et al.
9 citations
The effects of ibogaine were studied in 12 rats trained to perform in an 8-arm radial maze. In Phase I, the mean number of sessions to criterion and cumulative errors to criterion, as well as mean response rate, were determined for two groups of six animals in a task where only four arms were baited. Group 1 received a potentially neurotoxic dose of ibogaine (50 mg/kg IP administered twice,...
Pharmacology, Biochemistry, and Behavior
August 1, 1997
S M Pearl, L B Hough, D L Boyd et al.
58 citations
The present study demonstrates that the putative antiaddictive agent ibogaine produces more robust behavioral effects in female than in male rats and that these behavioral differences correlate with higher levels of ibogaine in the brain and plasma of female rats. There were no differences in basal locomotor activity between the sexes, and the response of rats to ibogaine differed between the...
Brain Research
June 13, 1997
Scott Helsley, Cynthia A Dlugos, R J Pentney et al.
19 citations
The present investigation assessed the chronic toxicity of ibogaine on cerebellar Purkinje cells in male Fischer 344 rats. A behaviorally active dose of ibogaine (10 mg/kg, i.p.) was administered to a group of six subjects every other day for 60 days while the control group received an equivalent volume of saline (1 ml/kg). Estimates of Purkinje cell number were determined using the optical...
Annals of the New York Academy of Sciences
May 30, 1997
F J Vocci, E D London
6 citations
New technologies utilized for monitoring brain function can be more sensitive in the assessment of desired or undesired pharmacological effects than can clinical examination. Nonetheless, careful case-by-case analysis is required to determine to what extent a change detected with a sensitive imaging modality will have clinical significance. Whereas in some instances the technology may suggest a...
Experimental and Clinical Psychopharmacology
May 1, 1997
I Moroz, Linda A. Parker, S Siegel
11 citations
The ability of ibogaine, injected 24 hr before amphetamine, to modify the establishment of amphetamine-induced place preference learning was assessed. A single injection of ibogaine blocked the establishment of amphetamine place preference after 1 or 2 conditioning trials, but it was less effective after 4 trials. The reduced effectiveness of ibogaine across multiple conditioning trials appears...
Brain Research
March 28, 1997
Hemendra N. Bhargava, Y J Cao, G M Zhao
19 citations
Ibogaine, an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga, has been claimed to decrease the self-administration of drugs of abuse like morphine, cocaine and alcohol. To determine whether these effects are mediated via opioid receptor systems, the effects of ibogaine and its metabolite, noribogaine on the antinociceptive actions of morphine, U-50,488H and...
Brain Research
March 28, 1997
Y J Cao, Hemendra N. Bhargava
18 citations
The effects of ibogaine, an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga, on the development of tolerance to the antinociception action of morphine, U-50,488H and [D-Pen2,D-Pen5]enkephalin (DPDPE), which are mu-, kappa- and delta-opioid receptor agonists, respectively, were determined in male Swiss-Webster mice. Mice were rendered tolerant to opioid receptor agonists...
Brain Research
February 28, 1997
Stanley D Glick, Isabelle M Maisonneuve, S M Pearl
38 citations
Ibogaine, a putatively anti-addictive alkaloid, binds to kappa-opioid and NMDA receptors. In the present study we investigated the roles of kappa-opioid and NMDA actions in mediating ibogaine's (40 mg/kg, i.p.) behavioral and neurochemical effects in rats. A combination of a kappa-opioid antagonist (norbinaltorphimine, 10 mg/kg, s.c.) and a NMDA agonist (NMDA, 20 mg/kg, i.p.) partially...